Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CSL Licenses Selexis Cell Line | Contract Pharma

What are you searching for?

Sign in
Breaking News

CSL Licenses Selexis Cell Line

CSL to use SUREtechnology for antibody

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CSL Ltd. has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody for Phase I clinical trials. Under the agreement, CSL has rights to use a cell line generated using the Selexis SUREtechnology Platform for the cGMP production of an undisclosed antibody.

“We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform,” said Dr. Igor Fisch, chief executive officer, Selexis SA. “This agreement represents Selexis’ commitment to helping our clients bring biologic therapeutic drugs into the clinic. We look forward to continuing to work with CSL.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics